E Fund Management Co. Ltd. lowered its stake in IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 51.7% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 2,024 shares of the medical research company's stock after selling 2,169 shares during the quarter. E Fund Management Co. Ltd.'s holdings in IQVIA were worth $398,000 at the end of the most recent quarter.
Several other hedge funds and other institutional investors have also recently bought and sold shares of IQV. Farther Finance Advisors LLC lifted its position in IQVIA by 35.2% in the third quarter. Farther Finance Advisors LLC now owns 407 shares of the medical research company's stock valued at $96,000 after purchasing an additional 106 shares during the last quarter. Impax Asset Management Group plc lifted its position in IQVIA by 9.7% in the third quarter. Impax Asset Management Group plc now owns 1,793,010 shares of the medical research company's stock valued at $423,885,000 after purchasing an additional 157,809 shares during the last quarter. Concurrent Investment Advisors LLC lifted its position in IQVIA by 5.6% in the third quarter. Concurrent Investment Advisors LLC now owns 5,679 shares of the medical research company's stock valued at $1,346,000 after purchasing an additional 301 shares during the last quarter. Graypoint LLC lifted its position in IQVIA by 6.3% in the third quarter. Graypoint LLC now owns 1,262 shares of the medical research company's stock valued at $299,000 after purchasing an additional 75 shares during the last quarter. Finally, Principal Financial Group Inc. lifted its position in IQVIA by 0.8% in the third quarter. Principal Financial Group Inc. now owns 209,021 shares of the medical research company's stock valued at $49,532,000 after purchasing an additional 1,750 shares during the last quarter. Institutional investors own 89.62% of the company's stock.
NYSE IQV opened at $191.69 on Friday. IQVIA Holdings Inc. has a 12 month low of $179.28 and a 12 month high of $261.72. The stock has a market cap of $33.80 billion, a P/E ratio of 25.56, a P/E/G ratio of 1.99 and a beta of 1.50. The stock's fifty day moving average price is $197.79 and its 200-day moving average price is $212.87. The company has a current ratio of 0.84, a quick ratio of 0.84 and a debt-to-equity ratio of 2.12.
IQVIA (NYSE:IQV - Get Free Report) last released its earnings results on Thursday, February 6th. The medical research company reported $2.90 EPS for the quarter, missing analysts' consensus estimates of $3.11 by ($0.21). IQVIA had a return on equity of 28.81% and a net margin of 8.91%. As a group, equities analysts forecast that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.
Several analysts have weighed in on IQV shares. Truist Financial reiterated a "buy" rating and issued a $263.00 price objective (up previously from $261.00) on shares of IQVIA in a research report on Monday, February 10th. Citigroup decreased their target price on IQVIA from $225.00 to $210.00 and set a "neutral" rating for the company in a report on Tuesday, March 4th. Stifel Nicolaus decreased their target price on IQVIA from $273.00 to $261.00 and set a "buy" rating for the company in a report on Friday, February 7th. Stephens assumed coverage on IQVIA in a report on Friday, December 20th. They set an "overweight" rating and a $250.00 target price for the company. Finally, Barclays decreased their target price on IQVIA from $255.00 to $235.00 and set an "overweight" rating for the company in a report on Monday, February 3rd. Four equities research analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $249.05.
View Our Latest Stock Report on IQV
IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider IQVIA, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and IQVIA wasn't on the list.
While IQVIA currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.